2. Lymphoma of Low Grade Malignancy
نویسندگان
چکیده
منابع مشابه
Low-grade lymphoma.
Folicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, shows considerable heterogeneity in its clinical behavior, representative of a biology that appears increasingly complex and diverse. As our knowledge of the molecular basis of FL increases, we strive for an integration between the bench and clinic that yields treatments based on our scientific understanding and bi...
متن کاملLow Grade Endometrial Stromal Sarcoma: Report of a Rare Uterine Malignancy
Endometrial stromal sarcoma represents a very rare pathological entity occurring as a malignant disease in women genital sphere, frequently in the age group of 40-50 years. Low grade endometrial stromal sarcoma (LGESS) is a rare uterine sarcoma constituting 0.2% of all the uterine malignancies with a good prognosis despite a tendency to recur. We report a case of 42 years old woman presented wi...
متن کاملPapillary Neoplasms of the Bronchus of Low-grade Malignancy.
In this paper we describe eight examples of papillary neoplasms of the bronchus in which atypical cytological features were present. In seven the lesion was localized and invasion was not present, in one extensive spread within the bronchial tree of a lobe had occurred but invasion into the lung parenchyma was doubtful. Lesions of this type receive little comment in the literature although they...
متن کاملMyopericytoma of low grade malignancy in the oral cavity
Myopericytoma (MPC) of the oral cavity is extremely rare. Herein reported is a case of MPC of low grade malignancy in the oral cavity. A 61-year-old man noticed a tumor of the cheek mucosa, and admitted to our hospital. Oral examination revealed a reddish elevated tumor of the cheek mucosa. Tumorectomy with wide margins was performed. The clinical diagnosis was pyogenic granuloma. Grossly, the ...
متن کاملOngoing trials in low-grade lymphoma
There are many therapies available for the management of low-grade lymphoma. With follicular lymphoma, for example, combination of chemotherapy and rituximab (immuno-chemotherapy) and consecutive maintenance therapy for 2 years is the current standard of care. To date, the most widely used regimen seems to be rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nihon Naika Gakkai Zasshi
سال: 2008
ISSN: 0021-5384,1883-2083
DOI: 10.2169/naika.97.1581